Bacterial infections can be treated with bacteriophages that show great specificity towards their bacterial host and can be genetically modified for different applications. However, whether and how bacteriophages can kill intracellular bacteria in human cells remains elusive. Here, using CRISPR/Cas selection, we have engineered a fluorescent bacteriophage specific for E. coli K1, a nosocomial pathogen responsible for urinary tract infections, neonatal meningitis and sepsis. By confocal and live microscopy, we show that engineered bacteriophages K1F-GFP and E. coli EV36-RFP bacteria displaying the K1 capsule, enter human cells via phagocytosis. Importantly, we show that bacteriophage K1F-GFP efficiently kills intracellular E. coli EV36-RFP in T24 human urinary bladder epithelial cells. Finally, we provide evidence that bacteria and bacteriophages are degraded by LC3-associated phagocytosis and xenophagy.
Bacteriophages or phages are viruses that infect bacteria and are the most abundant organisms on earth1. Bacteriophages present significant diversity and play an important role in the evolution of their host2. Bacteriophages have also been found inside the human body3,4,5,6 and more recently have been shown to enter via different mechanisms in human cells7,8. Bacteriophages are used to treat bacterial infections (phage therapy) and the interest in phage therapy has grown increasingly in recent years due to the emerging problem of antibiotic resistance of many bacterial pathogens9,10,11,12. Due to the recent advances of molecular and synthetic biology, bacteriophages can be easily genetically modified to obtain preferable characteristics for different applications13,14. A recently established efficient strategy applies the CRISPR/Cas System for the selection of recombinant bacteriophages15,16,17. This has opened new perspectives for phage therapy, by making genetically modified bacteriophages more easily attainable18. Such an approach could provide solutions to naturally resistant nosocomial bacterial pathogens, such as Escherichia coli K1. E. coli K1 is a gram-negative pathogen, responsible for a wide range of diseases, including sepsis, neonatal meningitis, urinary tract infections and inflammatory bowel syndrome19,20,21.
The virulence of E. coli K1 (E. coli O18:K1:H7) is attributed to its K1 polysaccharide capsule. The K1 capsular polysaccharide (K1 antigen) is an α-2-8-linked homopolymer of sialic acid (NeuNAc), which is responsible for the virulence and pathogenicity of these strains. The K1 antigen acts as a natural antiphagocytic barrier for the bacteria22. In addition, structural similarities between K1 and human tissue components indicate that immune tolerance may also be a factor of capsular E. coli pathogenesis23. Due to these characteristics, E. coli O18:K1:H7 is able to invade human endothelial and epithelial cells and cause the corresponding diseases referred to above21,24,25,26.
Phage K1F is a T7-like phage, which was first isolated in sewage and specifically infects E. coli strains that such as E. coli O18:K1:H727. Despite its similarities to phage T7 at the genome scale, phage K1F incorporates the endosialidase enzyme within its tail structure instead of the T7 tail fiber protein, which enables the attachment to- and degradation of the K1 polysaccharide capsule27. The K1 polysaccharide capsule has therefore been shown to be a barrier to T728 and a receptor for phage K1F.
Here we have developed a novel in vitro model system for studying phage therapy for E. coli K1 in T24 human urinary bladder epithelial cells. We have applied the CRISPR/Cas system to engineer fluorescent phage K1F that are able to infect the E. coli EV36 strain, an E. coli K12/K1 hybrid derivative with the ability to display a Kl polysaccharide capsule morphologically similar to that of E. coli K1 clinical isolates29. This system has enabled us to observe that both bacteria and bacteriophages invade T24 cells and that phage K1F kill intracellular E. coli EV36. We also show that upon being phagocytosed, bacteria and phages are degraded via different pathways: phage K1F is degraded mostly via LC3-assisted phagocytosis, whereas E. coli EV36 strain activates xenophagy. In the presence of both bacteria and bacteriophages, xenophagy is activated, indicating that the pathogen is sufficient to activate autophagy, whereas the bacteriophages on their own cannot activate autophagy to the same extent.
Phage K1F targets E. coli EV36-RFP strain
We initially confirmed the specificity of phage K1F for E. coli cells displaying a K1 capsule. For our experiments, we used the E. coli EV36 strain, an E. coli K-12-K1 hybrid derivative with the ability to express a Kl polysaccharide capsule morphologically similar to that of E. coli K1 clinical isolates29. We first compared in liquid culture the specificity of phage K1F and phage T7 for targeting the K1 capsule of the E. coli EV36 strain (Suppl. Fig. S1A left panel). By measuring the optical density at 600 nm over a period of 3.5 hours, we observed a drop in optical density in E. coli EV36 liquid culture only upon phage K1F addition. When no phage was added or when phage T7 was added, the E. coli EV36 bacteria continued to grow, indicating that solely phage K1F was capable of lysing them. We further tested phage K1F specificity towards an E. coli K-12 strain (MG1655 cells) (Suppl. Fig. S1A right panel) and we observed that in the presence of phage K1F or when no phage was added, E. coli MG1655 bacteria continued to grow and only upon T7 phage addition did the optical density of the liquid culture drop, indicating that T7 is specific to K-12 strains but not phage K1F. These results were further confirmed by plaque assays (Suppl. Fig. S1B). The phage K1F selected from a single plaque was further purified with a CsCl column and we performed transmission electron microscopy to reveal the exact pattern and structure of phage K1F (Suppl. Fig. S1C). This purified phage K1F was used for all our phage-related experiments and was the basis of the genetically engineered fluorescent phage K1F. In order to make E. coli EV36 bacteria easily visualized by microscopy, we transformed them with an RFP-expressing plasmid to provide them with a red colour (Suppl. Fig. S1D). Upon successfully obtaining E. coli EV36-RFP bacteria, we tested both in liquid culture (Suppl. Fig. S1E left panel) and with plaque assays (Suppl. Fig. S1E right panel) the ability of phage K1F to efficiently kill E. coli EV36-RFP. Our results showed that expression of RFP in E. coli EV36 did not seem to affect phage K1F’s ability to infect this strain, when compared with empty E. coli EV36 (Suppl. Fig. S1E left panel). All together our results confirm that phage K1F targets E. coli EV36-RFP.
Genome engineering of fluorescent phage K1F-GFP followed by CRISPR/Cas selection
To engineer a fluorescent phage K1F, we decided to integrate the superfolder green fluorescent protein (GFP) gene into the phage’s genome. Our primary aim was to generate translational fusions of GFP with gene10 (or g10), which encodes the major capsid protein gp29. It is worth noting, that gene10 can undergo a −1 translational frameshift in its 3′ region, resulting in the addition of 44 triplets. The protein encoded by this extended ORF (referred to as gene10b or g10b) functions as the minor capsid protein of the virion. For phage genome editing, we relied on the strategy of providing the donor DNA on a plasmid residing in the bacterial strain used to grow the targeted phage on (Fig. 1A), combined with the CRISPR/Cas selection of recombinant phages (Suppl. Fig. S2A,B)16,17. In our case, the strain hosting the donor DNA was E. coli EV3629. The donor DNA cassette, consisting of the GFP gene flanked by appropriate homology arms, was cloned into the pSB6A1 plasmid. We attempted the engineering of three different recombinant phages: phage K1Fg10::gfp would carry the gfp gene fused to the 3′ end of gene10, making a C-terminal GFP fusion of the major capsid protein (Fig. 1A,B); analogously, phage K1Fgfp::g10 would express the N-terminal GFP fusion of the major capsid protein (Fig. 1C) and phage K1Fg10b::gfp would harbour the gfp gene fused to the 3′ end of gene10b, making a C-terminal GFP fusion of the minor capsid protein (Fig. 1D). Plasmid and phage constructs are summarized in Table S3.
Growing phage K1F on E. coli EV36 carrying either of the three donor DNA molecules (Table S1) permitted the generation of phage mixtures containing both wild-type and recombinant phages. The presence of recombinants was indeed PCR-verified in each phage lysate using the GFPfw-g11rev primer pair (Suppl. Fig. S2C). However, the PCR-screening of plaques generated from these phage mixes did not result in the identification of recombinant plaques, thereby prohibiting the isolation of pure recombinant phage suspensions. To enrich recombinant phages within the phage mix, we applied CRISPR/Cas selection by growing the phage mix on E. coli EV 36 harbouring various pCas9 plasmid derivatives. The CRISPR/Cas9 machineries on these selection plasmids were engineered to cleave the wild-type gene10, but leave the gfp-fusion construct intact (Suppl. Fig. S2A,B). CRISPR/Cas selection of phages K1Fg10::gfp using the plasmid pCas9g10 however, did not yield recombinant plaques, nor did it increase the fraction of recombinants within the mix (data not shown). Next, the CRISPR/Cas selection process was applied to the phage mix of phages K1Fg10b::gfp. We used two different selection plasmids: pCas9K1FC1 and pCas9K1FC2, differing only in the encoded crRNA spacer sequences. After two rounds of growth of the phage mix on the two selection strains, recombinant plaques were observed with a frequency of 4/20, but only when using pCas9K1FC2 for selection. Phages retrieved from the positive plaques were further grown on E. coli EV36 cells and exposed to plaque assays to re-test for GFPfw-g11rev PCR fragment positivity. For all the four phage lysates, 5/5 plaques displayed the correct PCR product, verifying that the four original plaques of phages K1Fg10b::gfp were homogenous and that the C-terminal minor capsid gene fusions were stably maintained in the phage genomes. PCR analysis with primers g9fw-g11rev from all the four recombinant plaques yielded a single product of 2591 bp, as opposed to the 1831 bp obtained from phage K1F (Suppl. Fig. S2D), again supporting successful gfp integration and the clonal nature of the phages K1Fg10b::gfp. Sequencing the g9fw-g11rev region also verified correct integration, apart from a C to T transition at 22829, leading to Thr to Ile change in the C terminal region of the minor capsid protein. Each of the four phage K1Fg10b::gfp lines underwent fluorescent microscopic analysis (Fig. 2G,H,I and J). The stable fluorescent phages K1F (K1Fg10b::gfp) were used in the downstream experiments to detect phage K1F localisation in human cells.
K1-displaying E. coli EV36-RFP bacteria and engineered phage K1F-GFP invade T24 human urinary bladder epithelial cells
We next examined whether engineered phage K1F-GFP (approximately 1 × 108 PFU/ml) and E. coli EV36-RFP bacteria (approximately 2 × 107 CFU/ml) can invade T24 human urinary bladder epithelial cells. It has been shown previously that E. coli 018:K1:H7 can enter T24 cells via microtubule and microfilament dependent pathways24. We infected T24 cells with E. coli EV36-RFP and stained them with phalloidin (for the actin cytoskeleton) and DAPI (for the nucleus) (Fig. 2A,B). Using confocal microscopy, we observed that E. coli EV36-RFP could invade T24 cells. This was further confirmed with live time-lapse microscopy (Supplementary Fig. S7A). We then stained T24 cells with SiR-tubulin, a live cell microtubule probe and NucBlue Live ReadyProbes for nuclear staining in live cells (Fig. 2C) and we further incubated with C-terminal major capsid protein-labelled phage K1F-GFP mix (K1Fg10::gfp) (Fig. 2D), N-terminal major capsid protein-labelled phage GFP-K1F mix (K1Fgfp::g10) (Fig. 2E) and C-terminal minor capsid protein-labelled pure phage K1F-GFP (K1Fg10b::gfp) (Fig. 2F). In all the above cases, it was shown that phage K1F-GFP invaded T24 cells and localised inside vacuoles. Additionally, it was further confirmed by confocal microscopy (Suppl. Fig. S6A,B) and live time-lapse microscopy (Suppl. Fig. S7B), that phage K1F-GFP co-localised with E. coli EV36-RFP (Suppl. Fig. S6B) with great specificity (Suppl. Fig. S6A), indicating that the phage can target the bacteria in a human cell environment. We then continued analysing in vivo in more detail the pattern and localisation of the CRISPR-Cas selected four fractions (Suppl. Fig. S2D) of stable phage K1Fg10b::gfp (K1Fg10b::gfp-1 to -4, Fig. 2G–J). It was clearly shown that all the fractions of stable phage K1Fg10b::gfp could invade T24 cells and localise inside vacuoles, as pinpointed with arrows in the phalloidin staining (actin cytoskeleton) (Fig. 2G–J). Collectively these results show that both phage K1F-GFP and E. coli EV36-RFP bacteria can invade T24 human urinary bladder epithelial cells.
Engineered phage K1F-GFP efficiently kills intracellular E. coli EV36-RFP bacteria in T24 human urinary bladder epithelial cells
Next, we applied SYTOX Red Dead Cell staining to investigate the ability of phage K1F-GFP to efficiently target and kill both intracellular and extracellular E. coli EV36-RFP bacteria. We found that upon phage addition, the percentage of intracellular dead bacteria (Fig. 3A,C) increases significantly (Fig. 3B,C). E. coli EV36-RFP showed 29.1% co-localisation with SYTOX (n = 3 experiments), whereas upon phage K1F addition, this was increased to 77.6% co-localisation with SYTOX (n = 3 experiments). Additionally, we observed co-localisation between bacteria (red), phage (green) and SYTOX (grey), indicating that the bacteria infected by bacteriophage were dying. These results were further confirmed with live time-lapse microscopy (Suppl. Fig. S8A,B). T24 cells were infected with E. coli EV36-RFP (Suppl. Fig. S8A) and in the absence of phage K1F-GFP, the bacteria continued to grow and damaged the human cells. In the presence of phage K1F-GFP (Suppl. Fig. S8B), the E. coli EV36-RFP infection cleared over time and dead E. coli EV36-RFP began to float in the medium and made aggregates that moved via Brownian motions. In order to further confirm that the reduction in the intracellular bacteria is a consequence of phage infection, we performed again the SYTOX assay, this time applying phage K1F on E. coli MG1655 bacteria (n = 3 experiments), which as shown previously are not sensitive to phage K1F (Suppl. Fig. S8B) and phage T7 on E. coli EV36 bacteria (n = 3 experiments), which as shown previously are not sensitive to phage T7 (Suppl. Fig. S1A). Our results (Suppl. Fig. S3), present that upon phage addition, in both cases, there was no statistical significant increase in the percentage of intracellular dead bacteria, measured by co-localisation with SYTOX. These results enhance our observations that the increase in intracellular E. coli EV36 dead bacteria upon K1F phage addition is due to phage specificity to its host and phage infectivity rather than degradation of the bacteria by the T24 epithelial human cells. We next incubated the culture with gentamycin21,24 in order to clear it from extracellular bacteria and subsequently quantified the amount of intracellular E. coli EV36-RFP in T24 cells (Fig. 3D,F) to be 26.1% (n = 3 experiments). Upon bacteriophage addition, it was observed that phage K1F-GFP could co-localise with intracellular E. coli EV36-RFP (Fig. 3E,F) and could target more than half (16.2%, n = 3 experiments) of the intracellular E. coli EV36-RFP (of 26.1% as above). These results show that engineered phage K1F-GFP can kill intracellular E. coli EV36-RFP in T24 human urinary bladder epithelial cells. To estimate the concentration of bacteria to be added to T24 epithelial cells and further understand the correlation between concentration of bacteria added for incubation to human cells and the fraction of cells containing intracellular bacteria, we incubated T24 human cells as previously with E. coli EV36-RFP at concentrations ranging from 5 × 106 to 2 × 107 CFU (Suppl. Fig. S4). Based on our observations upon quantification, the concentration of added bacteria strongly correlates with the fraction of human cells harbouring intracellular bacteria. More specifically, when incubated with E. coli EV36-RFP (5.65 × 106 CFU/ml), 8.7% (n = 3 experiments) of T24 epithelial human cells were invaded, when incubated with E. coli EV36-RFP (1.13 × 107 CFU/ml), 12.74% (n = 3 experiments) of human cells were invaded, whereas, when incubated with E. coli EV36-RFP (2.26 × 107 CFU/ml), 22.74% (n = 3 experiments) of T24 epithelial human cells were invaded. Most of the invaded human cells (>95%) carried only a single bacterial cell within. The experiment was performed in biological triplicates and quantified by manually counting a minimum of 125 cells of each experimental condition. For the microscopy observation purposes, it was decided that bacterial concentration higher to 2.26 × 107 CFU/ml on our experimental setting was not preferred, due to defects caused to human cells soon after incubation, and thus causing difficulties to properly quantify the internalised bacteria in single cells. Equally, bacterial concentrations lower to 5.65 × 106 CFU/ml, resulted to a very small amount of intracellular bacteria and thus were not preferred either due to difficulties to identify intracellular bacteria in our microscopic observations.
To assess the dependence of the fraction of phage-containing human cells on the phage concentration, T24 cells were incubated with phage K1F-GFP, with PFUs ranging from approximately 1 × 105 to 1 × 107 (1.4 × 105, 1.28 × 106 and 1.27 × 107). The samples were observed on the confocal microscope and the number of human cells containing phage-vacuoles were quantified and were further divided by the number of total cells imaged. Upon confocal observation and quantification of internalized phages K1F-GFP, it was estimated that final PFU of approximately 1.28 × 106 resulted in 13.8% (n = 3 experiments) of phage K1F-GFP internalized in T24 human cells. PFU approx. 1 × 105 gave weak GFP signal, which we had difficulty to quantify and at PFU 1.27 × 107, we did not observe any difference compared to PFU 1.28 × 106, apart from the fact that the GFP signal looked brighter, possibly indicating a higher number of intracellular phages/higher number of phage virions in these cells.
We therefore concluded that the concentration of phages added to the cell culture did not influence the fraction of human cells that have up-taken them, but most probably affected the number of phages per human cell.
Based on previous observations, showing that C. difficile bacteriophages are more virulent to their host in the presence of human cells30, we performed similar experiments in our system to investigate whether this is also the case with phage K1F and E. coli EV36 in the presence of T24 epithelial human cells. Indeed, it was observed (Suppl. Fig. S5A), that the concentration of planktonic bacteria upon phage K1F addition and in the presence of T24 human epithelial cells decreased more rapidly compared to the same conditions in the absence of human cells (at 90 min, 30 min after phage K1F addition, the concentration of planktonic bacteria in the presence of human cells dropped to 1.09 × 108 CFU/ml (SD = 7.22 × 105) compared to 3.13 × 108 CFU/ml (SD = 2.16 × 107) in the absence of human cells, with a statistical significance of p = 0.00008). Additionally, the PFU of phage K1F was higher in the presence of human cells when this was compared to the PFU of phage K1F in the absence of human cells (at 120 min, the PFU/ml of phage K1F in the presence of human cells was 5.13 × 1011 (SD = 1.46 × 1011), whereas in the absence of human cells was estimated 5.65 × 109 (SD = 7.78 × 108), with a statistical significance of p = 0.018) (Suppl. Fig. S5B). Interestingly, even when phage K1F was not added, the concentration of planktonic E. coli EV36 in the presence of human cells was shown to drop initially (at 90 min, the concentration of planktonic bacteria in the presence of human cells dropped to 6.21 × 108 CFU/ml (SD = 5.91 × 107) compared to 2.92 × 109 CFU/ml (SD = 7.32 × 108) in the absence of human cells (Suppl. Fig. S5A) possibly due to the process of invasion to the T24 epithelial human cells. Overall, these results confirm the previous observation30 that bacteriophages become more efficient in killing their host, in a human cell environment.
Engineered phage K1F-GFP and E. coli EV36-RFP bacteria enter T24 human urinary bladder epithelial cells via phagocytosis and are degraded via LC3-associated phagocytosis
Our results obtained up to this point indicated that both bacteria and bacteriophage enter human cells via their engulfment into vacuoles (Fig. 2). To examine this further, we incubated T24 human urinary bladder epithelial cells with either E. coli EV36-RFP bacteria (approximately 2 × 107 CFU/ml), phage K1F-GFP (approximately 1 × 108 PFU/ml) or both. The treated cells were subsequently fixed and stained with phagosomal markers, starting with an Rab7 antibody, which has been shown to localise on phagosomes and to be required for phagosomal maturation31. We showed that Rab7 co-localises with E. coli EV36-RFP (Fig. 4A), phage K1F-GFP (Fig. 4B) and both E. coli EV36-RFP and phage K1F-GFP in combination (Fig. 4C), suggesting that E. coli EV36-RFP and phage K1F-GFP enter T24 cells via phagocytosis.
It is known that phagosomes are fused with lysosomes where their content is degraded32. To this end, we next tested lysosomal markers to identify whether these co-localise with bacteria and bacteriophage that were previously phagocytosed. Using the same conditions as previously, treated T24 cells were stained with a Cathepsin-L antibody, a marker for lysosomes33. We observed that Cathepsin-L co-localised with E. coli EV36-RFP (Fig. 4D), phage K1F-GFP (Fig. 4E) and both E. coli EV36-RFP and phage K1F-GFP in combination (Fig. 4F), suggesting that both bacteria and bacteriophage are delivered upon phagosome maturation into lysosomes to be degraded. Additionally, live imaging of T24 cells stained with Lysotracker Deep Red stain, was performed to track lysosomes based on their acidic properties. We observed that E. coli EV36-RFP, phage K1F-GFP and the two in combination co-localise with lysosomes (Fig. 5A).
It has been shown that cells use some components of the autophagy machinery to process extracellular cargo, in a process called LC3-associated phagocytosis32,34. To test this, we treated T24 cells as previously and stained with an LC3 antibody35. It was indeed confirmed that both E. coli EV36-RFP (Fig. 5B), phage K1F-GFP (Fig. 5C) and both E. coli EV36-RFP and phage K1F-GFP in combination (Fig. 5D), co-localise with LC3, suggesting that these are degraded via LC3-assisted phagocytosis.
E. coli EV36-RFP bacteria are degraded by xenophagy
It has been shown previously that intracellular bacteria can escape the initial phagosome and activate xenophagy (anti-bacterial autophagy) through selective autophagy receptors32. To test this, we incubated T24 human urinary bladder epithelial cells with either E. coli EV36-RFP bacteria (approximately 2 × 107 CFU/ml), phage K1F-GFP (approximately 1 × 108 PFU/ml) or both. The treated T24 cells were fixed and initially stained with a Galectin-8 antibody, which has been found to participate in xenophagy via the targeting of damaged vesicles upon bacterial invasion36. Here, Galectin-8 was found to co-localise with 50.6% n = 4 experiments) of intracellular E. coli EV36-RFP (Fig. 6A), but only with 24.4% (n = 4 experiments) of intracellular phage K1F-GFP (Fig. 6B,C). When intracellular E. coli EV36-RFP was infected with phage K1F-GFP, the co-localisation with Galectin-8 was increased to 100.0% (n = 3 experiments) (Fig. 6D).
We then repeated the same sets of experiments, this time staining with an NDP5237 antibody, a xenophagy receptor. Upon performing the experiment, we could see NDP52 co-localised with 47.8% (n = 3 experiments) of intracellular E. coli EV36-RFP (Fig. 6E), suggesting that cytosolic E. coli EV36-RFP are degraded via xenophagy. In cells incubated with phage K1F-GFP, it was observed that intracellular bacteriophages alone do not co-localise with NDP52 (n = 3 experiments) (Fig. 6F). In the presence of both bacteria and phages (Fig. 6G), the co-localisation of NDP52 with intracellular E. coli EV36-RFP infected with phage K1F-GFP, quantified from three different experiments, was found to be 24.9% (n = 3 experiments).
Finally, we repeated the same sets of experiments, this time staining with an ubiquitin antibody, as a marker for ubiquitinated proteins34. Ubiquitin was found to co-localise with 89.2% (n = 3 experiments) of intracellular E. coli EV36-RFP (Fig. 7A), but no co-localisation (n = 3 experiments) was observed with intracellular phage K1F-GFP (Fig. 7B). On the contrary, in the presence of both phage and bacteria (Fig. 7C) the co-localisation with ubiquitin increased to 97.8% (n = 3 experiments), indicating that the sole presence of bacteria increases ubiquitination dramatically.
These experiments were repeated in triplicates at minimum and the quantification corresponds to the average co-localisation with intracellular bacteria or bacteriophage across all experiments (Fig. 7D). Negative controls for all the secondary antibodies used for the co-localisation assays, verify the validity of these results (Suppl. Fig. S6C,D and E). Based on the above results, we propose that both E. coli EV36-RFP and phage K1F-GFP invade T24 epithelial human cells via phagocytosis and they can be degraded via LC3-assisted phagocytosis. When E. coli EV36-RFP escape the phagosome and become cytosolic they can activate xenophagy, whereas the bacteriophage alone cannot activate xenophagy. In the presence of both phage and bacteria, xenophagy is activated.
Bacteriophages are the most abundant viruses residing in the human body even in the absence of disease38,39,40. In various instances, the presence of bacteriophages within the human body and especially in the gut41,42,43,44,45 and in the bladder41, is regarded to function as a protective mechanism to the human body in the control of pathogens46,47. Recent studies have shown that bacteriophages can even invade human cells, either randomly, via transcytosis across epithelial cell layers7, via direct cellular interactions the bacteriophages might have with mammalian cells6,8,48,49 or via phagocytosis by macrophages50. In this study, we have engineered a fluorescent phage K1F that specifically targets the K1 polysaccharide capsule of E. coli EV36. We inserted a gfp gene into the phage genome by combining in vivo homologous recombination with CRISPR/Cas-selection. The engineering of fluorescent bacteriophages with the insertions of a fluorescent gene in their genome has been applied before, using various methodologies and different bacteriophages, such as T751, PP0152, T453, P2254,55 as well as the mycobacteriophages D2956 and DS6A57, where the fluorescent protein is either expressed in the capsid of the phage or in a non-essential region of its genome. We report for the first time the engineering of a fluorescent phage K1F and we have applied for the first time CRISPR/Cas to select for fluorescent bacteriophages. Even though we initially tried to integrate the gfp gene into the gene 10 (g10) of the phage’s genome, encoding for the major capsid protein of phage K1F, we were not able to isolate recombinant phage due to its fitness defect. This was confirmed by the observation of the formation of very small plaques obtained by plating the phage mix. Plaques with a ten-fold reduced diameter were found in frequencies of 1/94 and 1/135. PCR analysis of these plaques however yielded fragments of unexpected size, indicating the incorrect genomic integration of gfp. Our inability to fuse GFP to the C-terminal of gp29 may have resulted from at least two factors. First, the fusion of gfp to the 3′ of gene10 interrupts the ORF of gene10b. The lack of isolated plaques harbouring the correct construct most likely indicates that infective virions cannot assemble without the minor capsid protein. The presence of both wild type and recombinant phage genomes in the same cell however may allow the packaging of the recombinant DNA into wild type heads, explaining the existence and PCR-positivity of the phage K1F + phage K1Fg10::gfp mix. Second, the lack of a linker peptide between the capsid protein and GFP in the g10::gfp construct could severely reduce the fitness of the phage by inhibiting proper capsid protein folding58. To avoid these caveats, we attempted to fuse the gfp to gene 10b (g10b), resulting from a -1 translational frameshift in the 3′ region of g10, encoding for the minor capsid protein of the phage and the two remaining constructs were designed in a way to harbour a 3xGGGGS flexible linker connecting the fused proteins. For phage genome editing, we relied on the strategy of providing the donor DNA on a plasmid residing in the bacterial strain used to grow the targeted phage, combined with the CRISPR/Cas selection of recombinant phages16,17. With the above methodology, we managed to generate a stable recombinant fluorescent phage K1F. This has enabled us to observe the invasion of this phage into T24 human epithelial cells via phagocytosis, which was confirmed after our initial observations of invasion of fluorescent phage K1F into vacuoles, with the co-localisation of phage K1F with anti-Rab7 antibody, a protein known to localise into phagosomes and to participate in phagosome maturation31. The same was observed also for the E. coli EV36-RFP strain, which was also shown to invade T24 epithelial cells via phagocytosis and co-localise with anti-Rab7. It has been shown previously that E. coli K1 invades epithelial cells in a process depending on cytoskeletal rearrangements24 and regulated by the expression of the K1 capsule21 or via transcytosis59, assisted by the outer membrane protein expressed in E. coli K160. We clearly present here that the phage K1F by this invasion mechanism can efficiently kill the host bacteria in human cellular environment and importantly can also target intracellular E. coli EV36 bacteria. In order to further verify that the killing of the intracellular E. coli EV36 is attributed to the efficiency and specificity of phage K1F rather than the potential bacterial degradation by T24 epithelial cells, we performed control experiments with phage T7 and phage K1F coupled with bacterial strains non-sensitive to these phages (E. coli EV36 and E. coli MG1655 respectively) and upon these conditions we did not observe any increase in the killing of the bacterial strains upon addition of the aforementioned phages. These results confirmed that phage K1F is able to target intracellular host bacteria in human cell environment. This is a novel finding and very informative on the in vitro mechanism of phage therapy, providing knowledge that can accelerate this field in the future. Previous observations suggest that phage phiCDHS1 is more virulent to its host C. difficile bacteria in epithelial cell environment30. Our results enhance this finding, since we also observed that phage K1F presented higher killing efficiency towards its host E. coli EV36 bacteria in the presence of T24 epithelial human cells. Taken together, these results further confirm the hypothesis that there are specific interactions between phages and humans cells, possibly in forms of recognition receptors present in phages and human cells, which facilitate the bacterial clearance further during phage treatment30.
Lysosomes (phagolysosomes) are considered the endpoint in the phagocytosis where the mature phagosome fuses with a lysosome and any particles that are contained inside are completely degraded. We showed that both the phage and the bacteria upon phagocytosis, co-localise with Cathepsin-L, an endopeptidase enzyme that plays an important role in lysosome function33 and this was further confirmed with their co-localisation with Lysotracker Deep Red stain, which also a marker for lysosomes. This is indicative that phage K1F and E. coli EV36 bacteria enter the lysosomal degradative pathway, possibly as the result of constitutive maturation of phagosomes. In all the above cases, we showed that bacteria and phage together and independently were found in phagosomes and lysosomes. Uropathogenic E. coli bacteria have been shown to subvert the human innate immune system by escaping the phagosome61. When this vacuole is damaged by effectors released by the bacterium the glycan molecules that are typically enclosed within the cell compartment are exposed to the cytosol. The cell combats this via antibacterial autophagy (xenophagy) mechanisms32. This is typically via galectin-8 or ubiquitin dependent autophagy which both recruit the microtubule-associated protein 1A/1B-light chain (LC3). Our results suggests that E. coli EV36 bacteria and phage K1F are able to escape the phagosome and are targeted by autophagy mechanisms. On the contrary, in the presence of phage K1F alone, co-localisation was observed only with Galectin-8 in approximately 20% of the internalized phage, whereas 50% of bacteria alone were shown to co-localise with Galectin-8 and in the presence of both bacteria and phage this was increased to 100%. Phage K1F alone was not shown to co-localise at all neither with ubiquitin nor NDP52, both further down on the xenophagy pathway, indicating that bacteriophage alone cannot activate autophagy32. From these results, it seems that bacteriophage is degraded via LC3-assisted phagocytosis, rather than autophagy. This would suggest that the bacteriophage does not have the necessary machinery to escape the phagosome in which it was contained. Bacteriophages are found not to be toxic to human cells30 and thus we hypothesize based on our results that unlike their bacterial hosts, bacteriophages are not considered to be harmful for the human body. This hypothesis could explain the differential activation of mechanisms of degradation between phages and bacteria. The host pathogenic bacteria are known to be harmful for the human body and thus activate autophagy32. To our knowledge, there are no reports to this date on the mechanisms that bacteriophages are degraded by. This is the first report presenting a mechanism of bacteriophages’ degradation.
Our results overall reveal for the first time the mechanism via which bacteriophages that invade T24 human cells get degraded in comparison to the mechanism of invasion and degradation of their host bacteria. The fluorescent phage K1F that we have engineered provides an excellent tool to discover the pathway that bacteriophages follow in their interaction with bacteria and human cells. Finally, the engineering of this human tissue model system of phage therapy in E. coli EV36, mimicking the E. coli O18:K1:H729, a well-defined bacterial strain accountable for a multitude of conditions, has enabled us to unfold the cellular processes underpinning phage therapy. Our study provides an essential platform for engineering synthetic phages against E. coli or other antibiotic resistant bacteria as an innovative tool in the AMR fight.
Tissue cell culture
The human urinary bladder epithelial cell line, T24 (HTB-4), was acquired from LGC Standards (UK) an ATCC (American Type Culture Collection) affiliate. This cell line was originally derived from a bladder transitional cell carcinoma of a female patient.
The T24 cells were cultured in uncoated T75 flasks containing McCoy’s 5A (Modified) Medium (Gibco, MA) supplemented with 10% v/v Foetal Bovine Serum (FBS) (Labtech International, UK) and 1% v/v Penicillin-Streptomycin and were maintained at 37 °C in 5% CO2 under a humidified atmosphere.
Purification of bacteriophages
A single-clone preparation of phage K1F (kindly provided by Dr Dean Scholl27) was obtained by three consecutive infections of E. coli EV36 which is a K12/K1 hybrid developed by conjugation of Hfr kps + strain29 (kindly provided by Dr Eric R. Vimr). E. coli EV36 was used as an E. coli O18:K1:H17 analogue host to grow and purify phage K1F from a single plaque.
The single-clone phage K1F preparation was propagated to a high concentration over many infection cycles of cultures with increasing E. coli EV36 concentration. Each propagation culture was centrifuged at 3220 g for 15 minutes at 4 °C after bacterial clearance. The final culture was incubated with 0.2 M NaCl on ice for 1 hour to release phage particles from bacterial membranes and centrifuged at 5000 g for 45 minutes at 4 °C. The supernatant was recovered and incubated with 10% w/v PEG8000 for 16–18 hours at 4 °C to precipitate phage particles. The PEG solution was centrifuged for 25,000 g for 1 hour at 4 °C and the pellet was resuspended in a small volume SM-buffer62.
A CsCl density gradient was prepared in water with three solutions in densities of 1.7, 1.5 and 1.3 g/ml. CsCl was added to phage solution to achieve a density of 1.3 g/ml. The CsCl solutions were added to the centrifuge tube in equal volumes starting with the heaviest and subsequently were centrifuged at 125,000 g for 20 hours at 4 °C.
The resulting blue/grey band was extracted and transferred to a clamped dialysis tube with MWCO of 14 kDa and dialysed for 16–18 hours in a SM-buffer with high concentration of NaCl (1 M) followed by 2 times 2 hours in a SM-buffer with low concentration of NaCl (100 mM). Following dialysis the purified bacteriophage was stored at −20 °C.
Determination of phage infection efficiency in liquid culture
The phage infection efficiency and host selectivity were determined in a liquid culture assay. Bacterial cultures of E. coli EV36 strain and E. coli K-12 MG1655 (ATCC-47076) wild-type63, were inoculated in lysogeny broth (LB)64 and incubated in a rotating incubator at 37 °C.
The optical density was measured at 600 nm in 30 minute intervals. Cultures were inoculated with 1 µl wild type phage K1F (PFU 108) or 1 µl T765 (PFU 1010) phages once they reached their exponential phase after approximately two hours.
Transmission electron microscopy (TEM)
400 mesh copper grids with carbon graphite coating were cleaned and hydrophilized by glow discharge. A 10 µl drop of purified phage K1F was applied to the centre of the mesh and was incubated for 1 minute. The sample was removed and the mesh washed twice with 10 µl drops of water and finally negatively stained with 10 µl 2% uranyl acetate for 1 minute. Images were acquired using the Jeol 2100 transmission electron microscope.
Construction of E. coli EV36-RFP bacteria
In order to visualise the location and concentration of bacteria in a human cell environment, fluorescent E. coli EV36-RFP bacteria were constructed. E. coli EV36 bacteria were made electrocompetent as shown previously66 and were transformed with plasmid pSB1C3 (Registry of Standard Biological Parts. http://parts.igem.org/Main_Page) expressing the mRFP1 protein. Cells containing RFP were selected for with chloramphenicol (Cm: 25 µg/ml) and IPTG induction (0.5 mM).
Construction of genetically modified fluorescent bacteriophages
Strains, buffers and media
Phage dilutions were made in buffer Φ80 + containing 0.1 M NaCl, 0.01 M Tris (pH 7.9), 0.01 M CaCl2 and 0.01 M MgCl267. TBE buffer contained 45 mM Tris, 45 mM boric acid and 1 mM EDTA64. Bacteria were grown in lysogeny broth (LB)64. To make soft agarose for phage titering and plaque assays, LB-agar plates were overlain with 0.5% Seakem LE agarose (Lonza, Basel, Switzerland) containing 5 mM CaCl2 and 5 mM MgCl2. Antibiotics (Sigma-Aldrich, St. Louis, MO, USA) were used in the following concentrations: ampicillin (Ap): 50 µg/ml, chloramphenicol (Cm): 25 µg/ml.
Plasmid pSB6A1 was obtained from Registry of Standard Biological Parts. (http://parts.igem.org/Main_Page). Plasmid pCas9 (Addgene #42876) was the kind gift of Luciano Marraffini (The Rockefeller University), obtained via Addgene. The three donor plasmids used for phage K1F genome editing, pSBGFP, pSBN and pSBC3 were constructed by digesting a synthetic gene cassette ordered from Integrated DNA Technologies (Leuven, Belgium) with EcoRI and PstI and ligating to the corresponding restriction sites of the pSB6A1 plasmid. The synthetic gene cassettes comprised the superfolder Green Fluorescent Protein (GFP) gene flanked by two 150 bp-long homology boxes corresponding to segments of the phage K1F genome in the gene 10 region (for exact DNA sequences, see Table S1).
The three selection plasmids, pCas9g10, pCas9K1FC1 and pCas9K1FC2 were constructed by ligating the respective CRISPR spacers into the BsaI site of pCas9, as described previously68. The CRISPR spacers were designed by manually searching for 30 nt long stretches of the wild type phage K1F genome that span the integration site of GFP and end with an NGG. The spacers were synthesized as pairs of complementary oligonucleotides carrying the ends required for cloning (Table S2).
Phage propagation and titering
Routine bacteriophage procedures were conducted as described previously69. Briefly, for phage propagation, E. coli EV36 cells were grown by agitating at 37 °C in LB medium supplemented with 5 mM CaCl2 and 5 mM MgCl2 and were mixed with 106 plaque forming units (PFU) of phage K1F upon reaching an OD600 value of 0.5. Complete bacterial lysis was usually observed within 1–2 h of further shaking. At this point, 50 µl of chloroform was added and the lysate was shaken for 5 min, followed by pelleting of the cell debris and filtration of the supernatant with a 0.22 um Millex GP PES filter (Merck-Millipore, Carrigtwohill, Ireland) to obtain a cell-free phage lysate.
For phage titering and plaque assays, LB plates were overlain with 3 ml of molten soft agarose (cooled to 42 °C) containing 100 µl of midlog-phase E. coli EV36 cells. After solidification, 10 µl samples from each member of a dilution series of the phage lysate, ranging from the concentrated solution to 10−9 dilution was pipetted on top and let to dry. Individual plaques were already visible within the E. coli lawn at the appropriate dilutions after 4 h of incubation at 37 °C. The appropriately diluted phage lysate was then mixed with 100 µl of midlog-phase E. coli EV36 cells, mixed with 3 ml of molten soft agarose (cooled to 42 °C) and immediately poured onto LB plates at room temperature. After solidification, plates were incubated overnight at 37 °C. The plaque numbers counted the next day were used to calculate phage titers in PFU/ml. To estimate the fraction of recombinant phages in a phage mix, PCRs using primers GFPfw and g11rev were carried out on 1 µl samples from the dilution series of the phage mix. The ratio of the highest dilution factor still yielding a positive PCR and the phage titer (expressed as PFU/µl) gave the approximate fraction of recombinants within the phage mix.
Phage genome engineering via in vivo homologous recombination
To integrate the GFP gene into the genome of phage K1F, wild-type (wt) phages were propagated on E. coli EV36 cells harboring the appropriate donor plasmid for 1–3 rounds, as described above. The presence of recombinant phages in the obtained mixed lysate was verified by PCR analysis of the 1000-fold diluted lysate using primers GFPfw and g11rev (Table S2). To acquire pure recombinant phage cultures, the mixed lysate was propagated on E. coli EV36 carrying the appropriate selection plasmid. The obtained phage lysate was titered and the appropriate dilution was plated on E. coli EV36 to obtain individual plaques. In a plaque-assay, 10–20 plaques were aspirated with cut-off pipette tips as agarose plugs and released each into 40 µl of TBE buffer. After 4 h of incubation at 42 °C and a short vortexing, 0.5 µl of each sample was used as a template in PCR reactions using primers GFPfw and g11rev. The phage suspensions yielding a correct PCR product were titered and plated again on E. coli EV36 for a second round of plaque assay to warrant their purity. Positive phage suspensions obtained this way were propagated on E. coli EV36 to generate recombinant phage stocks to be further used in infection assays analyzed by microscopy.
Sequencing of recombinant bacteriophages
The sequence of the engineered K1Fg10b::gfp phage genome in the vicinity of the gfp insertion was verified by Sanger capillary sequencing using the ABI Big Dye Terminator v3.1 kit and a 3500 Series Genome Analyzer (Life Technologies-Thermo Fisher Scientific, Waltham, MA, USA). First, the region of interest was PCR-amplified using primers g9fw and g11rev. This 2591 bp-long PCR product was purified using the PCR Advanced PCR Cleanup System (Viogene, Taiwan, China) and sequenced with primers g9fw, g10fw, AS504 and g11rev. The obtained reads were aligned with the expected phage sequence using the Serial Cloner v2.6.1 (Serial Basics Inc.) to assemble to empirical g10b::gfp sequence map. The empirical sequence matched the expected sequence except for a C > T transition at 22264, resulting in a Thr377Ile mutation in the C terminal of g10b.
Immunofluorescence and confocal microscopy
Fluorescent immunocytochemistry was performed to identify the association of bacteria and phage with biological markers of the endolysosomal and autophagy pathways.
For invasion assays, the T24 cells were seeded onto uncoated 22 × 22 mm coverslips in 6-well plates at a density of approximately 4 × 104 cells/cm2 in McCoy’s 5A (Modified) Medium (supplemented with 10% v/v FBS only, without antibiotics at 37 °C) and were allowed to settle for 24 hours.
The culture media were aspirated and replaced with Leibovitz media (Lonza, Switzerland) that sustain cell viability in the absence of CO2 equilibrium and the cells were moved to an incubator appropriate for bacterial infections. While maintaining the confluent cultures at 37 °C, the cultures were incubated with E. coli EV36-RFP at OD 600 nm of approximately 0.4 to 0.6, which were added to 1 ml of Leibovitz media21,24 for 60 minutes following incubation with phages at PFU 1 × 108 for 60 minutes. In parallel, control cultures were incubated with bacteria or phage alone for 60 minutes. For the assays estimating the number of intracellular bacteria, upon infection, the cells were washed with PBS and fresh medium containing 100 µg/ml gentamycin was added for further 2 hours to kill the extracellular bacteria, prior to bacteriophage addition21,24. Phage K1F-GFP was then added as previously for 60 minutes. Immediately thereafter, the cultures were fixed in 4% paraformaldehyde (PFA) (ThermoFisher Scientific, MA), permeabilised in ice-cold PEM buffer with 0.05% Saponin and quenched with 50 mM NH4Cl in PBS. Appropriate wash step with PBS was performed between each step70. In order to estimate further the correlation between the number of intracellular bacteria and the concentration of bacteria added in human cells, T24 human cells were incubated with E. coli EV36-RFP at approximate concentrations ranging from 5 × 106 to 2 × 107 CFU/ml for 2 hours. The cells were fixed and further treated as described above.
The fixed cells were stained with the following primary antibodies diluted in 0.05% Saponin in PBS for 45 minutes at room temperature; 40 µg/ml Anti-RAB7 (Bioss Inc, MA), 1 µg/ml Anti-Cathepsin L (Abcam, UK), 5 µg/ml Anti-LC3B (Sigma-Aldrich, MO), 1 µg/ml Anti-CALCOCO2/NDP52 (Abcam, UK), 1 µg/ml Anti-Galectin-8 (R&D Systems, MN) or 1 µg/ml Anti-Mono- and polyubiquitinylated conjugates monoclonal antibody (FK2) (Enzo Life Sciences).
This was followed by conjugation with secondary Cy5 Affinipure Donkey Anti-Goat, Anti-Rabbit or Anti-mouse (Jackson ImmunoResearch, PA). Finally, the stained cells were mounted on microscope slides using Flouroshield Mounting Medium (Abcam, UK) containing DAPI nuclear stain.
Cultures containing GFP tagged bacteriophages were further enhanced with a GFP-Booster (Chromotek, Germany) at a concentration of 5 µg/ml alongside with the conjugation with secondary antibodies. In the context of visualising bacteria and phage in the cell environment without endolysosomal markers, an actin filament stain, Phalloidin CF680R Conjugate (Biotium, CA), was used at a concentration of 5 µg/ml.
All fixed cells were imaged using the Zeiss LSM 880 confocal microscope with Airyscan, with fluorophore excitation at the following wavelengths: DAPI at 405 nm, GFP at 488 nm, RFP at 561 nm and far-red (Cy-5) at 633 nm.
Quantification was performed by manually counting 10–20 images of each experimental condition. A minimum of 200 cells were counted of each experimental condition.
Live cell imaging
The T24 cells were seeded onto uncoated 35 mm glass bottom microscope dishes (ThermoFisher Scientific, MA) at a density of approximately 4 × 104 cells/cm2 in McCoy’s 5A (Modified) Medium (supplemented with 10% v/v FBS only) and were allowed to settle for 24 hours.
The culture media were aspirated and replaced with Leibovitz medium (Lonza, Switzerland) that sustain cell viability in the absence of CO2 equilibrium. While maintaining the confluent cultures at 37 °C, the cultures were incubated with E. coli EV36-RFP bacteria and phage K1F-GFP as previously. For the SYTOX Bacterial Death Assay, E. coli EV36-RFP at OD 600 nm of approximately 0.4 to 0.6, were added to 1 ml of Leibovitz media for 60 minutes. Fluorescent phage K1F was added, at PFU 1 × 108, for another 60 minutes. SYTOX Red dead cell stain (final conc. 5 nM) and 2 drops of NucBlue Live (ThermoFisher Scientific, MA) per 1 ml of Leibovitz medium was added to both samples for the last 20 minutes of the incubation. After the 20 minutes of SYTOX incubation, the cells were ready to be visualized under the Andor/Nikon Spinning Disk Confocal Laser Microscope.
Quantification was performed by manually counting 30–50 images of each experimental condition. A minimum of 200 cells were counted of each experimental condition.
For the live cell imaging with SiR tubulin (SPIROCHROME, Cytoskeleton, Inc.), T24 cells were seeded as previously onto uncoated 35 mm glass bottom microscope dishes (ThermoFisher Scientific, MA). 1 µL of SiR-tubulin and 1 µL Verapamil were added to 1 ml of McCoy’s 5A (Modified) Medium (supplemented with 10% v/v FBS only, free from Pen/Strep). This was added to the glass dishes containing confluent T24 cells to stain them for tubulin. After 1-hour of incubation the media were aspirated off to decrease the background of the SiR-tubulin staining and were infected with E. coli EV36-RFP bacteria and/or phage K1F-GFP as previously. In the last 20 minutes of infection, NucBlue Live (ThermoFisher Scientific, MA) was added as previously to stain for the nucleus. The samples were then visualized under the Andor/Nikon Spinning Disk Confocal Laser Microscope. In the live cell imaging provided in Supplementary Figures/Videos 7 and 8, when timing was different, it is mentioned on the corresponding figure legends.
E. coli EV36-RFP and phage K1F-GFP concentration dependent infection in T24 cells
T24 cells were seeded on uncoated coverslips in 6-well plates as described previously.
T24 cells maintained in Leibovitz media at 37 °C were incubated with E. coli EV36-RFP at approximate concentrations ranging from 5 × 106 to 2 × 107 CFU/ml and incubated for 2 hours. The cells were gently washed twice in PBS to remove planktonic bacteria and were subsequently fixed and permeabilised and stained with Phalloidin CF680R Conjugate as described in immunofluorescence and confocal microscopy section. The same process was repeated with phage K1F-GFP: 1 µl, 10 µl and 100 µl of phage K1F-GFP (stock PFU 1.4 × 108) was added in wells containing T24 cells (corresponding final PFUs/ml: 1.4 × 105, 1.28 × 106 and 1.27 × 107) and incubated for 1 h. The cells were then treated as previously and were consequently observed with confocal microscopy.
Time course measurements of planktonic bacteria and free phages
T24 cells were seeded in 6-well plates at a density of approximately 2.2 × 104 cells/cm2 in McCoy’s 5A (Modified) Medium supplemented with 10% v/v FBS and were allowed 48 hours to settle. The culture media was aspirated and replaced with Leibovitz media and maintained at 37 °C before commencing the experiment. E. coli EV36 and phage K1F were added to corresponding wells at approximate final concentrations of 5 × 106 CFU/ml and 3 × 103 PFU/ml respectively. Sampling was performed at 30 minutes intervals over a period of two hours.
Serial dilutions and plating for CFU determination was performed immediately after sampling, whereas samples taken for PFU determination were centrifuged at 3220 rpm for 15 minutes at 4 °C, immediately after sampling, to remove bacterial debris. The phage containing supernatant was stored at 4 °C for plating collectively, following the two-hour sampling period. CFU concentrations were determined by drop assay, plating 4 × 20 µl drops of each 10-fold dilution on LB plates and incubating these for 24 hours at 37 °C. Dilutions selected for CFU quantification accounted for a minimum of 80 colonies of a dilution. PFU concentrations were determined by overlay assay, plating 100 µl phage of each 10-fold dilution with 300 µl host log-phase bacteria in soft agar as described previously under phage propagation and titering. Dilutions selected for PFU quantification accounted for a minimum of 35 plaques of a dilution.
Each experiment was performed in biological triplicates and presented in graphs as the average +/− standard deviation of these.
Values are shown as the mean +/− SD of a minimum of three independent experiments in all figures. In liquid infection assays (Suppl. Fig. S1A), comparisons of means were carried out using a student t-test on the SPSS platform. In imaging quantification (Fig. 3C,F, 7D and Suppl. Fig. S4), a Student’s t-test corrected for multiple comparisons using the Holm-Sidak method was performed using GraphPad Prism 7. The calculated probability values (p-values) are displayed as p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****) and not statistical significant p ≥ 0.05 (ns).
All data generated or analysed during this study are included in this published article and its supplementary information files. The datasets generated during the current study are available from the corresponding author on reasonable request.
Suttle, C. A. Viruses in the sea. Nature 437, 356–361, https://doi.org/10.1038/nature04160 (2005).
Clokie, M. R., Millard, A. D., Letarov, A. V. & Heaphy, S. Phages in nature. Bacteriophage 1, 31–45, https://doi.org/10.4161/bact.1.1.14942 (2011).
Wahida, A., Ritter, K. & Horz, H. P. The Janus-Face of Bacteriophages across Human Body Habitats. PLoS Pathog 12, e1005634, https://doi.org/10.1371/journal.ppat.1005634 (2016).
Navarro, F. & Muniesa, M. Phages in the Human Body. Front Microbiol 8, 566, https://doi.org/10.3389/fmicb.2017.00566 (2017).
Bakhshinejad, B. & Ghiasvand, S. Bacteriophages in the human gut: Our fellow travelers throughout life and potential biomarkers of heath or disease. Virus Res 240, 47–55, https://doi.org/10.1016/j.virusres.2017.07.013 (2017).
Barr, J. J. A bacteriophages journey through the human body. Immunol Rev 279, 106–122, https://doi.org/10.1111/imr.12565 (2017).
Nguyen, S. et al. Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers. MBio 8, https://doi.org/10.1128/mBio.01874-17 (2017).
Lehti, T. A., Pajunen, M. I., Skog, M. S. & Finne, J. Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells. Nat Commun 8, 1915, https://doi.org/10.1038/s41467-017-02057-3 (2017).
Chan, B. K. et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018, 60–66, https://doi.org/10.1093/emph/eoy005 (2018).
Forti, F. et al. Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.02573-17 (2018).
Khalifa, L. et al. Defeating Antibiotic- and Phage-Resistant Enterococcus faecalis Using a Phage Cocktail in Vitro and in a Clot Model. Front Microbiol 9, 326, https://doi.org/10.3389/fmicb.2018.00326 (2018).
Burrowes, B., Harper, D. R., Anderson, J., McConville, M. & Enright, M. C. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther 9, 775–785, https://doi.org/10.1586/eri.11.90 (2011).
Sagona, A. P., Grigonyte, A. M., MacDonald, P. R. & Jaramillo, A. Genetically modified bacteriophages. Integr Biol (Camb) 8, 465–474, https://doi.org/10.1039/c5ib00267b (2016).
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J. & Lu, T. K. Genetically Engineered Phages: a Review of Advances over the Last Decade. Microbiol Mol Biol Rev 80, 523–543, https://doi.org/10.1128/MMBR.00069-15 (2016).
Manor, M. & Qimron, U. Selection of Genetically Modified Bacteriophages Using the CRISPR-Cas System. Bio Protoc 7, https://doi.org/10.21769/BioProtoc.2431 (2017).
Martel, B. & Moineau, S. CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages. Nucleic Acids Res 42, 9504–9513, https://doi.org/10.1093/nar/gku628 (2014).
Kiro, R., Shitrit, D. & Qimron, U. Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. RNA Biol 11, 42–44, https://doi.org/10.4161/rna.27766 (2014).
Bardy, P., Pantucek, R., Benesik, M. & Doskar, J. Genetically modified bacteriophages in applied microbiology. J Appl Microbiol 121, 618–633, https://doi.org/10.1111/jam.13207 (2016).
Vimr, E. R. & Steenbergen, S. M. Mobile contingency locus controlling Escherichia coli K1 polysialic acid capsule acetylation. Mol Microbiol 60, 828–837, https://doi.org/10.1111/j.1365-2958.2006.05158.x (2006).
Krishnan, S., Chang, A. C., Stoltz, B. M. & Prasadarao, N. V. Escherichia coli K1 Modulates Peroxisome Proliferator-Activated Receptor gamma and Glucose Transporter 1 at the Blood-Brain Barrier in Neonatal Meningitis. J Infect Dis 214, 1092–1104, https://doi.org/10.1093/infdis/jiw306 (2016).
King, J. E., Aal Owaif, H. A., Jia, J. & Roberts, I. S. Phenotypic Heterogeneity in Expression of the K1 Polysaccharide Capsule of Uropathogenic Escherichia coli and Downregulation of the Capsule Genes during Growth in Urine. Infect Immun 83, 2605–2613, https://doi.org/10.1128/IAI.00188-15 (2015).
Silver, R. P., Aaronson, W. & Vann, W. F. The K1 capsular polysaccharide of Escherichia coli. Rev Infect Dis 10(Suppl 2), S282–286 (1988).
Vimr, E. & Lichtensteiger, C. To sialylate, or not to sialylate: that is the question. Trends Microbiol 10, 254–257 (2002).
Meier, C., Oelschlaeger, T. A., Merkert, H., Korhonen, T. K. & Hacker, J. Ability of Escherichia coli isolates that cause meningitis in newborns to invade epithelial and endothelial cells. Infect Immun 64, 2391–2399 (1996).
Huang, S. H. et al. Identification and characterization of an Escherichia coli invasion gene locus, ibeB, required for penetration of brain microvascular endothelial cells. Infect Immun 67, 2103–2109 (1999).
Kim, K. J., Elliott, S. J., Di Cello, F., Stins, M. F. & Kim, K. S. The K1 capsule modulates trafficking of E. coli-containing vacuoles and enhances intracellular bacterial survival in human brain microvascular endothelial cells. Cell Microbiol 5, 245–252 (2003).
Scholl, D. & Merril, C. The genome of bacteriophage K1F, a T7-like phage that has acquired the ability to replicate on K1 strains of Escherichia coli. J Bacteriol 187, 8499–8503, https://doi.org/10.1128/JB.187.24.8499-8503.2005 (2005).
Scholl, D., Adhya, S. & Merril, C. Escherichia coli K1′s capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 71, 4872–4874, https://doi.org/10.1128/AEM.71.8.4872-4874.2005 (2005).
Vimr, E. R. & Troy, F. A. Regulation of sialic acid metabolism in Escherichia coli: role of N-acylneuraminate pyruvate-lyase. J Bacteriol 164, 854–860 (1985).
Shan, J. et al. Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells. Sci Rep 8, 5091, https://doi.org/10.1038/s41598-018-23418-y (2018).
Chua, C. E., Gan, B. Q. & Tang, B. L. Involvement of members of the Rab family and related small GTPases in autophagosome formation and maturation. Cell Mol Life Sci 68, 3349–3358, https://doi.org/10.1007/s00018-011-0748-9 (2011).
Randow, F. & Youle, R. J. Self and nonself: how autophagy targets mitochondria and bacteria. Cell Host Microbe 15, 403–411, https://doi.org/10.1016/j.chom.2014.03.012 (2014).
Bhutani, N., Piccirillo, R., Hourez, R., Venkatraman, P. & Goldberg, A. L. Cathepsins L and Z are critical in degrading polyglutamine-containing proteins within lysosomes. J Biol Chem 287, 17471–17482, https://doi.org/10.1074/jbc.M112.352781 (2012).
Lai, S. C. & Devenish, R. J. LC3-Associated Phagocytosis (LAP): Connections with Host Autophagy. Cells 1, 396–408, https://doi.org/10.3390/cells1030396 (2012).
Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1–222, https://doi.org/10.1080/15548627.2015.1100356 (2016).
Thurston, T. L., Wandel, M. P., von Muhlinen, N., Foeglein, A. & Randow, F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 482, 414–418, https://doi.org/10.1038/nature10744 (2012).
Thurston, T. L., Ryzhakov, G., Bloor, S., von Muhlinen, N. & Randow, F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat Immunol 10, 1215–1221, https://doi.org/10.1038/ni.1800 (2009).
Rascovan, N., Duraisamy, R. & Desnues, C. Metagenomics and the Human Virome in Asymptomatic Individuals. Annu Rev Microbiol 70, 125–141, https://doi.org/10.1146/annurev-micro-102215-095431 (2016).
Breitbart, M. & Rohwer, F. Method for discovering novel DNA viruses in blood using viral particle selection and shotgun sequencing. Biotechniques 39, 729–736, https://doi.org/10.2144/000112019 (2005).
Moustafa, A. et al. The blood DNA virome in 8,000 humans. PLoS Pathog 13, e1006292, https://doi.org/10.1371/journal.ppat.1006292 (2017).
Malki, K. et al. Seven Bacteriophages Isolated from the Female Urinary Microbiota. Genome Announc 4, https://doi.org/10.1128/genomeA.01003-16 (2016).
De Sordi, L., Khanna, V. & Debarbieux, L. The Gut Microbiota Facilitates Drifts in the Genetic Diversity and Infectivity of Bacterial Viruses. Cell Host Microbe 22, 801–808 e803, https://doi.org/10.1016/j.chom.2017.10.010 (2017).
Lusiak-Szelachowska, M., Weber-Dabrowska, B., Jonczyk-Matysiak, E., Wojciechowska, R. & Gorski, A. Bacteriophages in the gastrointestinal tract and their implications. Gut Pathog 9, 44, https://doi.org/10.1186/s13099-017-0196-7 (2017).
Mirzaei, M. K. & Maurice, C. F. Menage a trois in the human gut: interactions between host, bacteria and phages. Nat Rev Microbiol 15, 397–408, https://doi.org/10.1038/nrmicro.2017.30 (2017).
Dalmasso, M., Hill, C. & Ross, R. P. Exploiting gut bacteriophages for human health. Trends Microbiol 22, 399–405, https://doi.org/10.1016/j.tim.2014.02.010 (2014).
Gorski, A. & Weber-Dabrowska, B. The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 62, 511–519, https://doi.org/10.1007/s00018-004-4403-6 (2005).
Barr, J. J. et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci USA 110, 10771–10776, https://doi.org/10.1073/pnas.1305923110 (2013).
Aalto, J., Pelkonen, S., Kalimo, H. & Finne, J. Mutant bacteriophage with non-catalytic endosialidase binds to both bacterial and eukaryotic polysialic acid and can be used as probe for its detection. Glycoconj J 18, 751–758 (2001).
Dabrowska, K., Switala-Jelen, K., Opolski, A., Weber-Dabrowska, B. & Gorski, A. Bacteriophage penetration in vertebrates. J Appl Microbiol 98, 7–13, https://doi.org/10.1111/j.1365-2672.2004.02422.x (2005).
Hodyra-Stefaniak, K. et al. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci Rep 5, 14802, https://doi.org/10.1038/srep14802 (2015).
Slootweg, E. J. et al. Fluorescent T7 display phages obtained by translational frameshift. Nucleic Acids Res 34, e137, https://doi.org/10.1093/nar/gkl600 (2006).
Oda, M., Morita, M., Unno, H. & Tanji, Y. Rapid detection of Escherichia coli O157:H7 by using green fluorescent protein-labeled PP01 bacteriophage. Appl Environ Microbiol 70, 527–534 (2004).
Kazmierczak, Z. et al. Molecular imaging of T4 phage in mammalian tissues and cells. Bacteriophage 4, e28364, https://doi.org/10.4161/bact.28364 (2014).
Vinay, M. et al. Phage-Based Fluorescent Biosensor Prototypes to Specifically Detect Enteric Bacteria Such as E. coli and Salmonella enterica Typhimurium. PLoS One 10, e0131466, https://doi.org/10.1371/journal.pone.0131466 (2015).
O’Neil, A., Prevelige, P. E., Basu, G. & Douglas, T. Coconfinement of fluorescent proteins: spatially enforced communication of GFP and mCherry encapsulated within the P22 capsid. Biomacromolecules 13, 3902–3907, https://doi.org/10.1021/bm301347x (2012).
da Silva, J. L. et al. Application of BRED technology to construct recombinant D29 reporter phage expressing EGFP. FEMS Microbiol Lett 344, 166–172, https://doi.org/10.1111/1574-6968.12171 (2013).
Mayer, O. et al. Fluorescent Reporter DS6A Mycobacteriophages Reveal Unique Variations in Infectibility and Phage Production in Mycobacteria. J Bacteriol 198, 3220–3232, https://doi.org/10.1128/JB.00592-16 (2016).
Werner, S., Marillonnet, S., Hause, G., Klimyuk, V. & Gleba, Y. Immunoabsorbent nanoparticles based on a tobamovirus displaying protein A. Proc Natl Acad Sci USA 103, 17678–17683, https://doi.org/10.1073/pnas.0608869103 (2006).
Burns, J. L., Griffith, A., Barry, J. J., Jonas, M. & Chi, E. Y. Transcytosis of gastrointestinal epithelial cells by Escherichia coli K1. Pediatr Res 49, 30–37, https://doi.org/10.1203/00006450-200101000-00010 (2001).
Fagan, R. P. & Smith, S. G. The Hek outer membrane protein of Escherichia coli is an auto-aggregating adhesin and invasin. FEMS Microbiol Lett 269, 248–255, https://doi.org/10.1111/j.1574-6968.2006.00628.x (2007).
Dikshit, N. et al. Intracellular Uropathogenic E. coli Exploits Host Rab35 for Iron Acquisition and Survival within Urinary Bladder Cells. PLoS Pathog 11, e1005083, https://doi.org/10.1371/journal.ppat.1005083 (2015).
Castro-Mejía, J. L. et al. Optimizing protocols for extraction of bacteriophages prior to metagenomic analyses of phage communities in the human gut. Microbiome 3, 64, https://doi.org/10.1186/s40168-015-0131-4 (2015).
Savalia, D., Robins, W., Nechaev, S., Molineux, I. & Severinov, K. The role of the T7 Gp2 inhibitor of host RNA polymerase in phage development. J Mol Biol 402, 118–126, https://doi.org/10.1016/j.jmb.2010.07.012 (2010).
Sambrook, J. Molecular cloning: a laboratory manual. (Third edition. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press,  ©2001, 2001).
Molineux, I. J. The T7 group (2006).
Gonzales, M. F., Brooks, T., Pukatzki, S. U. & Provenzano, D. Rapid protocol for preparation of electrocompetent Escherichia coli and Vibrio cholerae. J Vis Exp, https://doi.org/10.3791/50684 (2013).
Blattner, F. R., Fiandt, M., Hass, K. K., Twose, P. A. & Szybalski, W. Deletions and insertions in the immunity region of coliphage lambda: revised measurement of the promoter-startpoint distance. Virology 62, 458–471 (1974).
Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L. A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31, 233–239, https://doi.org/10.1038/nbt.2508 (2013).
Feher, T., Karcagi, I., Blattner, F. R. & Posfai, G. Bacteriophage recombineering in the lytic state using the lambda red recombinases. Microb Biotechnol 5, 466–476, https://doi.org/10.1111/j.1751-7915.2011.00292.x (2012).
Sagona, A. P. et al. PtdIns(3)P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody. Nat Cell Biol 12, 362–371, https://doi.org/10.1038/ncb2036 (2010).
This work was supported by the BBSRC Future Leader Fellowship (ref. BB/N011872/1) to A.P.S. and a MIBTP DTP PhD studentship to C.M.O. S.F.S.H was supported by a MBio Master’s Program in the University of Warwick. T.F. was supported by the National Research, Development, and Innovation Office of Hungary (NKFIH) Grant No. K119298 and the GINOP-2.3.2-15-2016-00001 grant. We want to acknowledge Dr Dean Scholl, AvidBiotics Corporation, for providing us with the phage K1F and Drs Eric R. Vimr and. Susan M. Steenbergen for giving us the E. coli EV36 strain. We also want to acknowledge WISB (Warwick Integrative Synthetic Biology Centre), for letting us use their Microscopy Equipment.
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Møller-Olsen, C., Ho, S.F.S., Shukla, R.D. et al. Engineered K1F bacteriophages kill intracellular Escherichia coli K1 in human epithelial cells. Sci Rep 8, 17559 (2018). https://doi.org/10.1038/s41598-018-35859-6
- Fluorescent Phage
- Mixed Phage
- Phage Therapy
- Minor Capsid Protein
Environmental Science and Pollution Research (2021)
Environmental Chemistry Letters (2021)
Bacteriophage K1F targets Escherichia coli K1 in cerebral endothelial cells and influences the barrier function
Scientific Reports (2020)
Folia Microbiologica (2020)